Merck KGaA Stock Dips On Weak Q3 Profit; Cuts FY18 EBITDA Pre View

Merck KGaA reported Wednesday a sharp decline in its third-quarter profit, while sales increased despite negative currency impacts. Further, the German drugmaker lowered its fiscal 2018 forecast for EBITDA pre, but confirmed organic EBITDA pre view. The company also lifted its organic net sales growth forecast.
RTT – Earnings

BEST DEAL UPDATE:

BMW Stock Down On Weak Q3 Profit; Confirms FY18 Outlook

Shares of BMW Group declined around 2 percent in German trading after the auto giant reported Wednesday weak profit in its third quarter, despite growth in revenues. Further, the company confirmed its fiscal 2018 forecast for lower profit and automotive revenues. In terms of its core business, BMW said it had always expected 2018 to be a challenging year.
RTT – Earnings

BEST DEAL UPDATE:

Volkswagen 9M Profit Climbs On Strong Deliveries; Backs FY18 View; Stock Up

Shares of Volkswagen Group were gaining around 4 percent in the early morning trading in Germany after the automaker reported Tuesday higher profit in the first nine months of fiscal 2018 with increased deliveries. Further, the company confirmed its fiscal year targets, despite continuously challenging market conditions.
RTT – Top Story

BEST DEAL UPDATE:

Daimler Q3 Results Weak; Sees Lower EBIT, Higher Revenues & Unit Sales In FY18

Shares of Daimler AG (DDAIF.PK) were gaining around 3 percent in German trading after the automaker on Thursday said it expects slight increase in fiscal 2018 revenues and unit sales. The company is also confident for the fourth quarter with continued high demand.
RTT – Earnings

BEST DEAL UPDATE:

Amphenol Raises FY18 Outlook – Quick Facts

While reporting its third-quarter financial results, Amphenol Corp. (APH) said that for the full year 2018, the company now expects to achieve sales in a range of $ 8.040 billion to $ 8.080 billion, an increase over 2017 of 15 percent, as well as adjusted earnings per share in a range of $ 3.68 to $ 3.70, an increase over 2017 of 18 percent to 19 percent.
RTT – Earnings

BEST DEAL UPDATE:

Roche 9-month Sales Rise; Backs FY18 Outlook

Swiss drug major Roche Holding AG reported Wednesday higher sales in its first nine months of fiscal 2018, with growth in Pharmaceuticals sales in all regions except Europe. Diagnostics Division also recorded higher sales in all regions. Looking ahead to fiscal 2018, Roche confirmed its outlook for higher results at constant exchange rates.
RTT – Earnings

BEST DEAL UPDATE: